Lorajmine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Lorajmine
Accession Number
DB13651
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
F96VX65849
CAS number
47562-08-3
Weight
Average: 402.92
Monoisotopic: 402.1710204
Chemical Formula
C22H27ClN2O3
InChI Key
LAHDERDHXJFFJU-ZWNKPRIXSA-N
InChI
InChI=1S/C22H27ClN2O3/c1-3-11-12-8-15-19-22(13-6-4-5-7-14(13)24(19)2)9-16(25(15)21(11)27)18(12)20(22)28-17(26)10-23/h4-7,11-12,15-16,18-21,27H,3,8-10H2,1-2H3/t11-,12-,15-,16-,18-,19-,20+,21+,22+/m0/s1
IUPAC Name
(1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-14-hydroxy-8-methyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2,4,6-trien-18-yl 2-chloroacetate
SMILES
CC[C@@H]1[C@@H](O)N2[C@H]3C[C@]45[C@H](OC(=O)CCl)[C@H]3[C@H]1C[C@H]2[C@@H]4N(C)C1=CC=CC=C51

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Acebutolol.
AceprometazineThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Aceprometazine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Lorajmine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Acetyldigoxin.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Lorajmine.
AdenosineThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Adenosine.
AgmatineAgmatine may increase the arrhythmogenic activities of Lorajmine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Lorajmine.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lorajmine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
34990507
ChEBI
135646
Wikipedia
Lorajmine
ATC Codes
C01BA12 — Lorajmine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.438 mg/mLALOGPS
logP2.96ALOGPS
logP2.83ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)13.33ChemAxon
pKa (Strongest Basic)7.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.47 m3·mol-1ChemAxon
Polarizability42.62 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as ajmaline-sarpagine alkaloids. These are organic compounds containing either of the ajmalan, sarpagan skeleton, or derivative thereof. The Sarpagine (Akuammidine) group, based on the sarpagan nucleus, arises from bond formation between C-16 and C-5 of the corynantheine precursor. Ajmaline alkaloids are based on a 17,19-secoyohimban skeleton (oxayohimban) which is invariably present as an ether.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ajmaline-sarpagine alkaloids
Sub Class
Not Available
Direct Parent
Ajmaline-sarpagine alkaloids
Alternative Parents
Beta carbolines / Quinolizidines / Quinuclidines / Dialkylarylamines / Aralkylamines / Azepanes / Piperidines / Benzenoids / Alpha-halocarboxylic acid derivatives / Amino acids and derivatives
show 9 more
Substituents
Sarpagine-skeleton / Beta-carboline / Pyridoindole / Quinolizidine / Indole or derivatives / Dialkylarylamine / Quinuclidine / Tertiary aliphatic/aromatic amine / Azepane / Aralkylamine
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:46 / Updated on September 02, 2019 20:04